MRTX - Mirati Therapeutics, Inc.
| Previous Close | 63.71 |
| Open | 63.87 |
| Bid | 58.95 x 2900 |
| Ask | 68.00 x 800 |
| Day's Range | 63.36 - 66.73 |
| 52 Week Range | 23.50 - 66.73 |
| Volume | 966,006 |
| Avg. Volume | 756,180 |
| Market Cap | 2.107B |
| Beta (3Y Monthly) | 2.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.99 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 64.33 |
- PR Newswire•15 hours ago
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that harbor KRAS G12C mutations. "Today we have achieved an important milestone in the battle against cancers driven by KRAS mutations, one of the most common and difficult to treat patient populations. MRTX849 has been designed to specifically target KRAS G12C mutations, which are thought to be responsible for at least 14% of non-small cell lung adenocarcinoma, 4% of colorectal cancer, and subsets of other types of cancers," said Charles Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati.
- ACCESSWIRE•23 hours ago
Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
- ACCESSWIRE•6 days ago
Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause
TORONTO, ON / ACCESSWIRE / January 10, 2019 / The Wealthy Biotech Trader (or ''WBT''), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharma, medical device stocks making news and subsequent market moves, would like to update investors on several breakthroughs in cancer therapies hitting the market. Stock investors have soured on biotech companies over the past several months, as demonstrated by the SPDR S&P Biotech ETF (XBI), off 30% since June, and the NYSE Biotechnology Index (NYSE:NBI), which has dropped from 3500 in mid-2018 to just under 3000 at year-end, and a host of their component companies and others in addition. One of those is Propanc Biopharma, Inc. (OTCQB:PPCB), an Australian biotech company with strong management and technology that has the potential to help millions of cancer patients worldwide.
- Zacks•7 days ago
Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4%
Mirati Therapeutics (MRTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- PR Newswire•9 days ago
Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®)
SAN DIEGO , Jan. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) a clinical-stage targeted oncology company, today announced a clinical collaboration with Bristol-Myers Squibb Company ...
- PR Newswire•14 days ago
Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
SAN DIEGO , Jan. 2, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco ...
- PR Newswire•27 days ago
Mirati Therapeutics Added To NASDAQ Biotechnology Index
SAN DIEGO , Dec. 20, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that it has been selected for addition to the NASDAQ Biotechnology ...
- Insider Monkey•last month
Hedge Funds Are Buying Mirati Therapeutics, Inc. (MRTX)
We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]
- PR Newswire•last month
Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors
SAN DIEGO , Dec. 10, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the appointment of Maya Martinez-Davis to the Company's Board ...
- GlobeNewswire•last month
Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar — Discovering Underlying Factors of Influence
NEW YORK, Dec. 04, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Benzinga•2 months ago
The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 29) Allakos Inc (NASDAQ: ALLK ) Emergent Biosolutions Inc ...
- PR Newswire•2 months ago
Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849
"KRAS mutations, like the G12C mutation, are recognized as drivers of multiple tumor types, including non-small cell lung cancer and colorectal cancers. Efforts over the last 25 years to develop drugs to inhibit mutant KRAS have been largely unsuccessful," said James Christensen, Ph.D., Chief Scientific Officer, Mirati Therapeutics.
Market Realist•2 months agoMirati Therapeutics Stock Has Delivered Solid Growth in 2018
Mirati Therapeutics hit a 52-week high of $65.35 on July 31. In November, Mirati Therapeutics presented the preliminary biomarker data from the ongoing Phase 2 clinical trial of its sitravatinib and Bristol-Myers Squibb’s Opdivo combination therapy. Mirati Therapeutics is conducting the Phase 2 trial of the sitravatinib and Opdivo combination therapy for the evaluation of its safety and efficacy in the treatment of non-small cell lung cancer.
- PR Newswire•2 months ago
Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference
SAN DIEGO , Nov. 20, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will participate in a fireside chat at the 30th Annual Piper Jaffray Healthcare ...
- PR Newswire•2 months ago
Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, announced preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib in combination with nivolumab (OPDIVO®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. The data will be presented today in a poster and also in an oral presentation on Saturday, November 10th. The ongoing Phase 2 clinical trial is evaluating the safety and efficacy of sitravatinib in combination with an anti-PD-1 immune checkpoint inhibitor, in patients who have experienced documented disease progression following prior checkpoint inhibitor therapy. Efficacy data were recently presented at the October 2018 European Society for Medical Oncology (ESMO) Congress.
- PR Newswire•2 months ago
Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting
SAN DIEGO, Nov. 9, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical-stage targeted oncology company, announced data from the ongoing Phase 2 clinical trial of mocetinostat in combination with durvalumab (IMFINZI®) in non-small cell lung cancer (NSCLC) patients at the Society for Immunotherapy of Cancer (SITC) 33rd Annual Meeting in Washington, D.C. The data will be presented today in a poster and also in an oral presentation on Sunday, November 11th. The clinical trial is a Phase 2 study evaluating the efficacy and safety of mocetinostat in combination with durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in patients with NSCLC who have experienced documented disease progression following prior treatment with an immune checkpoint inhibitor.
- PR Newswire•2 months ago
Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors
HKEX: 06160) in a Phase 1b clinical trial to assess the safety and tolerability, pharmacokinetics and preliminary anti-tumor activity of Mirati's sitravatinib in combination with BeiGene's investigational anti-PD1 antibody, tislelizumab, in patients with advanced solid tumors. The clinical trial is currently enrolling patients in China and Australia. BeiGene's ability to rapidly enroll patients into this clinical trial has the potential to significantly expand and accelerate our development efforts for sitravatinib and provide access to additional patient populations," said Charles Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati.
- PR Newswire•2 months ago
Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference
SAN DIEGO , Nov. 7, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the 27th Annual Credit Suisse Healthcare Conference in Scottsdale, ...
- Associated Press•2 months ago
Mirati: 3Q Earnings Snapshot
The San Diego-based company said it had a loss of 85 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was ...
- PR Newswire•2 months ago
Mirati Therapeutics Reports Third Quarter Financial Results
SAN DIEGO , Nov. 6, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter ended September 30, ...
- PR Newswire•2 months ago
Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting
- Preliminary biomarker data from the ongoing Phase 2 clinical trial of sitravatinib and nivolumab in NSCLC patients will be presented in an oral presentation - Updated data from the ongoing Phase 2 clinical ...
- PR Newswire•3 months ago
Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer
SAN DIEGO, Oct. 30, 2018 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology company, announced today that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2 trial with the initial goal to evaluate safety, tolerability and pharmacokinetics of the Company's KRAS G12C inhibitor, MRTX849, in patients with advanced solid tumors. Phase 2 expansion cohorts will enroll patients whose tumors are driven by KRAS G12C positive mutations. The Phase 2 portion of the trial in patients with non-small cell lung cancer (NSCLC) or colorectal cancer (CRC) may provide proof of concept and the basis for accelerated approval.
- Investor's Business Daily•3 months ago
Biotech Dives After Lung Cancer Regimen With Bristol Disappoints
Mirati Therapeutics crashed Monday after its immunotherapy cancer treatment with Bristol-Myers Squibb's Opdivo disappointed in lung cancer.
- Investor's Business Daily•3 months ago
These Companies Are Dragging Biotech Stocks Into A Pit On Cancer Tests
Mirati Therapeutics and Clovis Oncology dragged biotech companies into a pitfall Monday after studies of their cancer treatments disappointed during a meeting in Europe.
